OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
November 24, 2020
HMA and EMA have released a joint statement on the appropriate route for companies to submit marketing authorization applications and the approval processes for vaccines.
November 19, 2020
A second global Phase III clinical trial investigating the safety and efficacy of a two-dose regimen of JNJ-78436735 has been initiated by Johnson & Johnson.
Interim results of AZD1222 trial have demonstrated lower reactogenicity in older adults, and strong immune responses across all adult age groups.
Moderna has reported that EMA's CHMP has started a rolling review of mRNA-1273—Moderna’s COVID-19 vaccine candidate.
November 09, 2020
Interim efficacy data suggests the Pfizer/BioNTech has an efficacy rate above 90%.
November 03, 2020
Amorphous solid dispersions are a useful tool in overcoming solubility issues, but they have not yet reached full potential in commercial success.
An optimal engineering design is crucial for aseptic operation and cleaning.
October 29, 2020
Two FDA-funded projects at RCPE will look at real-time monitoring and control of drug tablet coating and developing a digital twin for drug production control.
October 27, 2020
The Phase III clinical trial of NVX-CoV2373 is expected to be fully enrolled in the UK and will begin in the US and Mexico by the end of November 2020.
September 25, 2020
A clinical trial to enroll up to 10,000 volunteers across the UK will assess whether NVX-CoV2373 is effective in the prevention of COVID-19.